Form 4: AngioDynamics Director Michael Tarnoff Receives Annual Stock Compensation

AngioDynamics, Inc. Director Michael E. Tarnoff was granted 17,675 restricted stock units as part of his regular annual compensation, which vested immediately.

Summary

• Michael E. Tarnoff, a Director of AngioDynamics, Inc. (ANGO), acquired 17,675 shares of common stock on July 16, 2025.
• These shares represent restricted stock units granted as regular annual compensation for his service as a director.
• The restricted stock units vested immediately upon grant.
• Following this transaction, Michael E. Tarnoff beneficially owns 83,378 shares of AngioDynamics common stock.
• Separately, a Substitute Power of Attorney was executed on January 20, 2025, appointing Lawrence T. Weiss as a substitute attorney-in-fact for Michael E. Tarnoff, superseding previous arrangements.

Sentiment

Score: 6

Explanation: The document reports a routine compensation grant to a director, which is a positive for aligning interests but does not indicate significant operational or financial news. The Power of Attorney update is administrative.

Positives

• The grant of restricted stock units to Director Michael E. Tarnoff aligns his interests with those of shareholders, as his compensation is tied to the company's equity performance.
• The immediate vesting of the restricted stock units provides clear ownership and reduces future administrative complexities.

Negatives

• No specific negative aspects are identified in this routine compensation filing.

Risks

• The Substitute Power of Attorney remains in effect until revoked, superseded, or the PoA Party is no longer required to file SEC forms, which could lead to a lapse in authorization if not properly managed.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details a routine compensation grant to a director, which is a standard practice across industries to align executive and board interests with shareholder value. It does not provide specific insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The grant of restricted stock units as annual director compensation is a common practice in publicly traded companies, including those in the medical technology sector like AngioDynamics.
• While specific compensation amounts vary by company size and industry, this type of equity-based compensation is standard for aligning director incentives with long-term company performance.
• No specific comparable companies or projects are mentioned in the document to allow for a detailed comparative assessment.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this document.

Related Party Transactions

• The restricted stock unit grant is a form of compensation and not a related party transaction in the context of business dealings or asset transfers.

Stakeholder Impact

• Shareholders: The grant of equity compensation to a director aligns the director's financial interests with shareholder value creation.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• No specific future actions, events, or milestones are mentioned in this filing beyond the ongoing requirement for the reporting person to file Forms 3, 4, and 5 as long as they are subject to Section 16.

Key Dates

Keywords

AngioDynamics, ANGO, SEC Form 4, Director Compensation, Restricted Stock Units, RSU Grant, Insider Trading, Beneficial Ownership, Corporate Governance, Power of Attorney